Browse by Medical Category
Accepting New Patients
Rabab Jafri is an attending pediatric endocrinologist at the MassGeneral Hospital for Children. Her clinical interests include the care of children with diabetes, as well as other endocrine disorders related to the thyroid gland, adrenal gland, growth and puberty.
Go To Programs
MassGeneral Hospital for Children
Go To Specialties
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Rabab Jafri is a pediatric endocrinologist with particular interests in pediatric diabetes and pancreatic disease. She completed a pediatric residency at the University of Illinois at Chicago, and a fellowship in pediatric endocrinology at the Massachusetts General Hospital for Children (MGHfC). During her fellowship she became interested in diabetes related advocacy and was invited to Capitol Hill by the Endocrine Society to discuss the importance of NIH funding for research and controlling insulin pricing with state senators. Her research during fellowship involved trials with the artificial pancreas in populations with disorders of blood sugar regulation. She has presented her work at regional, national and international forums.
The overarching goal of my research is the incorportaion of technology within diabetes care to optimize the care of patients with disorders of glucose regulation. Since 2016, I have been involved in trials testing the Bionic Pancreas, with the aim of automating blood glucose regulation. This is a hormonal delivery device utilizing a model predictive algorithm and delivering insulin, or, in its bi-hormonal configuration, both insulin and glucagon. This system has proven effective in patients with type 1 diabetes with ongoing studies testing its efficacy in patients with type 2 diabetes, post-bariatric hypoglycemia and congenital hyperinsulinism. I am interested in studying the differences in physiology related to the underlying mechanism behind diabetes in these conditions and what modifications to thebionic pancreas are needed to improve glycemia in conditions other than type 1 diabetes. As part of this, I am also studying novel analogues of insulin and glucagon which are designed to provide not only optimized blood sugar control but also reduced patient burden and hence enhance quality of life. Our group is looking forward to conducting bridging and pivotal studies across multiple centers in the US in the next 1-2 years with the fully integrated dual-chamber bionic pancreas device (iLetRM).
View my most recent publications at PubMed
Peer reviewed publications
Back to Top